Comparative evaluation of serum TGF-β1 and PDGF-BB levels across patients with normal coronary arteries, stable coronary artery disease, and acute coronary syndrome.
4 affiliations
- 1Department of Cardiology, Karabük Training and Research Hospital, Karabük, Turkey.
- 2Department of Cardiology, Kırıkkale University Faculty of Medicine, Ankara Road Sehitler Campus, Yahsihan, Kırıkkale, 71450, Turkey.
- 3Department of Cardiology, Kırıkkale University Faculty of Medicine, Ankara Road Sehitler Campus, Yahsihan, Kırıkkale, 71450, Turkey. [email protected].
- 4Department of Biochemistry, Kırıkkale University Faculty of Medicine, Kırıkkale, Turkey.
Abstract
Background
To compare serum levels of Transforming Growth Factor-Beta (TGF-β) and Platelet-Derived Growth Factor-BB (PDGF-BB) among patients with normal coronary arteries (NCA) and those with coronary artery disease (CAD) subclasses [stable CAD and acute coronary syndrome (ACS)], and to evaluate their potential diagnostic value and discriminatory power, particularly in identifying stable CAD.Methods
This single-center, cross-sectional study included 176 patients who underwent coronary angiography. Participants were classified into normal coronary artery (NCA; symptomatic control), stable CAD, and ACS groups. Demographic, clinical, and biochemical data were recorded. Blood samples were collected for the analysis of TGF-β1 and PDGF-BB levels using ELISA kits.Results
Hypertension and diabetes mellitus were significantly more prevalent in the stable CAD group compared to others (p < 0.001). Both TGF-β and PDGF-BB levels were significantly elevated in patients with stable CAD compared to individuals with normal coronary arteries and those with ACS (p < 0.001). Multivariate regression analysis identified hypertension, diabetes, TGF-β, and PDGF-BB as independent predictors of stable CAD (p < 0.01 for all). ROC curve analysis demonstrated good diagnostic performance for TGF-β and PDGF-BB individually (AUC = 0.847, 0.798, respectively), with combined assessment further improving accuracy (AUC = 0.924).Conclusion
Serum TGF-β and PDGF-BB levels are significantly increased in stable CAD patients relative to those with ACS and normal coronary anatomy. The combined evaluation of these biomarkers provides high diagnostic accuracy in distinguishing stable CAD, underscoring their potential role in the non-invasive assessment of chronic atherosclerotic disease. These findings support the use of TGF-β and PDGF-BB as complementary biomarkers for early identification and risk stratification in stable CAD.
Related
- Multicentre medicoeconomic evaluation of cardiac magnetic resonance imaging for predicting coronary artery disease in left ventricular dysfunction: The CAMAREC study design
- Association of peripheral CD4⁺/CD8⁺ T-cell ratio with SYNTAX score and coronary stenosis severity in patients with coronary artery disease.
- Cognitive frailty in patients with acute coronary syndromes: A scoping review
- Circulating Interleukin-36 Alpha, Beta, Gamma, and Interleukin-37 Levels in Patients With Chronic Coronary Syndrome
- Identification and validation of cholesterol homeostasis and NK cell-associated predictive and therapeutic models for Coronary atherosclerotic heart disease patients with ST-elevated myocardial infarction: Insights from artificial intelligence and multi-omics
BibTeX
@article{kucuksevgili2026comparative,
title = {{Comparative evaluation of serum TGF-β1 and PDGF-BB levels across patients with normal coronary arteries, stable coronary artery disease, and acute coronary syndrome.}},
author = {Veli Küçüksevgili and Haksun Ebinç and Hüseyin Kandemir and Burçin Küçüksevgili and Üçler Kısa},
journal = {BMC cardiovascular disorders},
year = {2026},
month = jul,
doi = {10.1186/s12872-026-06346-y},
url = {https://europepmc.org/article/MED/42907952},
note = {CC BY-NC-ND},
}
RIS
TY - JOUR
TI - Comparative evaluation of serum TGF-β1 and PDGF-BB levels across patients with normal coronary arteries, stable coronary artery disease, and acute coronary syndrome.
AU - Veli Küçüksevgili
AU - Haksun Ebinç
AU - Hüseyin Kandemir
AU - Burçin Küçüksevgili
AU - Üçler Kısa
PY - 2026
DA - 2026/07/01
JO - BMC cardiovascular disorders
DO - 10.1186/s12872-026-06346-y
UR - https://europepmc.org/article/MED/42907952
AB - Background To compare serum levels of Transforming Growth Factor-Beta (TGF-β) and Platelet-Derived Growth Factor-BB (PDGF-BB) among patients with normal coronary arteries (NCA) and those with coronary artery disease (CAD) subclasses [stable CAD and acute coronary syndrome (ACS)], and to evaluate their potential diagnostic value and discriminatory power, particularly in identifying stable CAD.Methods This single-center, cross-sectional study included 176 patients who underwent coronary angiography. Participants were classified into normal coronary artery (NCA; symptomatic control), stable CAD, and ACS groups. Demographic, clinical, and biochemical data were recorded. Blood samples were collected for the analysis of TGF-β1 and PDGF-BB levels using ELISA kits.Results Hypertension and diabetes mellitus were significantly more prevalent in the stable CAD group compared to others (p < 0.001). Both TGF-β and PDGF-BB levels were significantly elevated in patients with stable CAD compared to individuals with normal coronary arteries and those with ACS (p < 0.001). Multivariate regression analysis identified hypertension, diabetes, TGF-β, and PDGF-BB as independent predictors of stable CAD (p < 0.01 for all). ROC curve analysis demonstrated good diagnostic performance for TGF-β and PDGF-BB individually (AUC = 0.847, 0.798, respectively), with combined assessment further improving accuracy (AUC = 0.924).Conclusion Serum TGF-β and PDGF-BB levels are significantly increased in stable CAD patients relative to those with ACS and normal coronary anatomy. The combined evaluation of these biomarkers provides high diagnostic accuracy in distinguishing stable CAD, underscoring their potential role in the non-invasive assessment of chronic atherosclerotic disease. These findings support the use of TGF-β and PDGF-BB as complementary biomarkers for early identification and risk stratification in stable CAD.
SN - 1471-2261
ER -